These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9183308)

  • 1. Predictors of weight loss during treatment with d-fenfluramine.
    Toornvliet AC; Pijl H; Hopman E; Westendorp RG; Meinders AE
    J Intern Med; 1997 May; 241(5):401-6. PubMed ID: 9183308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotoninergic drug-induced weight loss in carbohydrate craving obese patients.
    Toornvliet AC; Pijl H; Hopman E; Elte-de Wever BM; Meinders AE
    Int J Obes Relat Metab Disord; 1996 Oct; 20(10):917-20. PubMed ID: 8910095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial weight loss as a predictor of response to obesity drugs.
    Dhurandhar NV; Blank RC; Schumacher D; Atkinson RL
    Int J Obes Relat Metab Disord; 1999 Dec; 23(12):1333-6. PubMed ID: 10643693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of dexfenfluramine on weight loss and cardiovascular risk factors in female patients with upper and lower body obesity.
    Ditschuneit HH; Flechtner-Mors M; Adler G
    J Cardiovasc Risk; 1996 Aug; 3(4):397-403. PubMed ID: 8946272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of dexfenfluramine on eating behavior and body weight of obese patients: results of a field study of Isomeride in Austrian general practice].
    Geyer G; Haidinger G; Francesconi M; Langmayr N; Prager R; Schoberberger R; Toplak H; von Kalckreuth G; Kunze M
    Acta Med Austriaca; 1995; 22(5):95-101; 104-9. PubMed ID: 8651045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The treatment of the obese non-insulin-dependent patient with d-fenfluramine].
    Daniele E; Coco MP
    Clin Ter; 1996 Apr; 147(4):199-204. PubMed ID: 8766352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower fat intake as a predictor of initial and sustained weight loss in obese subjects consuming an otherwise ad libitum diet.
    Carmichael HE; Swinburn BA; Wilson MR
    J Am Diet Assoc; 1998 Jan; 98(1):35-9. PubMed ID: 9434648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach.
    Wadden TA; Berkowitz RI; Vogt RA; Steen SN; Stunkard AJ; Foster GD
    Obes Res; 1997 May; 5(3):218-26. PubMed ID: 9192396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors.
    Swinburn BA; Carmichael HE; Wilson MR
    Int J Obes Relat Metab Disord; 1996 Nov; 20(11):1033-40. PubMed ID: 8923161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term drug treatment of obesity in a private practice setting.
    Atkinson RL; Blank RC; Schumacher D; Dhurandhar NV; Ritch DL
    Obes Res; 1997 Nov; 5(6):578-86. PubMed ID: 9449143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between health-related quality of life and weight loss.
    Kolotkin RL; Crosby RD; Williams GR; Hartley GG; Nicol S
    Obes Res; 2001 Sep; 9(9):564-71. PubMed ID: 11557837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors.
    Chow CC; Ko GT; Tsang LW; Yeung VT; Chan JC; Cockram CS
    Diabetes Care; 1997 Jul; 20(7):1122-7. PubMed ID: 9203448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine.
    Hensrud DD; Connolly HM; Grogan M; Miller FA; Bailey KR; Jensen MD
    Mayo Clin Proc; 1999 Dec; 74(12):1191-7. PubMed ID: 10593346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical studies with dexfenfluramine: from past to future.
    Guy-Grand B
    Obes Res; 1995 Nov; 3 Suppl 4():491S-496S. PubMed ID: 8697048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical cost savings of treating obesity with weight loss medications.
    Greenway FL; Ryan DH; Bray GA; Rood JC; Tucker EW; Smith SR
    Obes Res; 1999 Nov; 7(6):523-31. PubMed ID: 10574509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. d-Fenfluramine selectively suppresses carbohydrate snacking by obese subjects.
    Wurtman J; Wurtman R; Mark S; Tsay R; Gilbert W; Growdon J
    Int J Eat Disord; 1985; 4(1):89-99. PubMed ID: 11540865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged use of a very low calorie diet (Cambridge diet) in massively obese patients attending an obesity clinic: safety, efficacy and additional benefit from dexfenfluramine.
    Finer N; Finer S; Naoumova RP
    Int J Obes; 1989; 13 Suppl 2():91-3. PubMed ID: 2613434
    [No Abstract]   [Full Text] [Related]  

  • 19. A pilot study investigating the effect of Caralluma fimbriata extract on the risk factors of metabolic syndrome in overweight and obese subjects: a randomised controlled clinical trial.
    Astell KJ; Mathai ML; McAinch AJ; Stathis CG; Su XQ
    Complement Ther Med; 2013 Jun; 21(3):180-9. PubMed ID: 23642949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tolerance and acceptability of dexfenfluramine in the long-term treatment of obesity in private practice. ESIM Group].
    Héraïef E
    Rev Med Suisse Romande; 1997 Jan; 117(1):19-24. PubMed ID: 9082531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.